Results 131 to 140 of about 30,845,260 (288)

Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?

More than 25% of the adult population worldwide and approximately 50–75% of patients with type 2 diabetes are diagnosed with non-alcoholic fatty liver disease.
Michalis K. Picolos, Georgios S. Papaetis, Anastasia Sacharidou   +2 more
core   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Obesity and hypertension in type 2 diabetes: exploring central and peripheral effects of glucagon-like peptide-1 receptor signalling

Glucagon-like peptide 1 is a hormone involved in the regulation of glucose. Glucose-dependent activation of brain GLP-1R stimulates GLP-1 secretion from the L-cells of the intestine in response to ingested nutrients and it enters the blood stream to ...
Robinson, Louise E.
core  

Olfactory Dysfunction and Metabolic Syndrome Components: A Systematic Review and Meta‐Analysis

The Laryngoscope, EarlyView.
ABSTRACT Objective To elucidate the association between olfactory dysfunction (OD) and metabolic syndrome components. Data Sources PubMed (National Library of Medicine—National Institutes of Health), Scopus (Elsevier), CINAHL Complete (EBSCOhost), and the Cochrane Library (Wiley) databases were searched from inception through March 23rd, 2026.
Neeti Gandra, Kaitlyn A. Roberts, Shaun A. Nguyen, Pete Peters, Lauren A. Howser, Zachary M. Soler, Rodney J. Schlosser   +6 more
wiley   +1 more source

Comparison of GLP-1 Receptor Agonists’ Effect on Weight in those with Schizophrenia: A Systematic Review [poster] [PDF]

School of Nursing CapstonesIntroduction: Individuals with schizophrenia experience a shortened life expectancy primarily due to cardiovascular and metabolic complications associated with antipsychotic induced weight gain.
Landel, Katherine
core  

Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults

The Laryngoscope, EarlyView.
Table 1 succinctly quantifies the time‑dependent association between GLP‑1RA/GIP therapy and laryngeal symptoms, demonstrating modest but statistically robust increases in outcomes such as cough and voice/resonance disorders by 6 months. It provides clinically actionable absolute risks, odds ratios, and hazard ratios that can directly inform counseling,
Priyanka Shah, David Kayekjian, Shaun A. Nguyen, Kirsten Meenan, Ashli K. O’Rourke   +4 more
wiley   +1 more source

Comparison of GLP-1 Receptor Agonists’ Effect on Weight in those with Schizophrenia: A Systematic Review [paper] [PDF]

School of Nursing CapstonesIntroduction: Individuals with schizophrenia experience a shortened life expectancy primarily due to cardiovascular and metabolic complications associated with antipsychotic induced weight gain.
Landel, Katherine
core  

Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider, Divyani Garg, Vassilena Iankova, Thomas Klopstock   +3 more
wiley   +1 more source

High‐Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy

Movement Disorders, EarlyView.
Abstract Background Multiple system atrophy (MSA) is a rare and devastating neurodegenerative disorder. Accumulating clinical and preclinical evidence suggests that diabetes and insulin resistance may adversely influence MSA pathophysiology. Objective We investigated the potential association between diabetes, impaired glucose homeostasis, and MSA ...
Marie‐Laure Arotcarena, Anna Delamarre, Miguel Lopez‐Cuina, Hugo Martin, Elio Balpe, Xavier Fioramonti, Erwan Bezard, Wassilios G. Meissner   +7 more
wiley   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source